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Introduction
Gene therapy of malignant tumours using suicide genes is performed in two steps. First, the tumour is infected with recombinant viruses to introduce the suicide gene into the cells. To obtain a sufficient level of enzyme activity in the tumour, multiple infections may be necessary. For the planning and the individualization of gene therapy, the enzyme activity induced in the tumour has to be estimated in order to express levels of enzyme sufficient for therapy before the application of the prodrug. This may be done with radiolabeled specific substrates of the suicide enzyme which has been transferred into the tumour. [1] [2] [3] [4] In the second step, the nontoxic prodrug is administered systemically. The measurement of therapy effects on the tumour metabolism after the onset of systemic prodrug application may be useful for the prediction of therapeutic outcome at an early stage of the treatment. Positron emission tomography (PET) using tracers of tumour metabolism has been applied for the evalu-ation of treatment response during chemotherapy and radiotherapy in a variety of tumours, [5] [6] [7] [8] [9] indicating that these tracers deliver useful parameters for the early assessment of therapeutic efficacy. However, PET has not yet been applied to monitoring tumours during suicide gene therapy.
In a previous in vitro study with genetically modified Morris hepatoma cells bearing the herpes simplex virus thymidine kinase (HSVtk) gene, we were able to show that 2-fluoro-2-deoxyglucose (FDG) uptake is enhanced shortly after therapy with ganciclovir (GCV). This increase in FDG uptake was mainly due to an increase in the transport capacity of the tumour cells. 10 The present study was undertaken to evaluate in vivo the effects of gene therapy in the same tumour model.
Results

Growth inhibition
To determine the therapeutic efficacy in vivo, animals bearing a control tumour (LXSN6) or the HSVtk-expressing tumour (LXSNtk8) were treated with GCV or with sodium chloride. The control tumours showed no growth inhibition during GCV treatment, whereas the HSVtk-881 expressing tumours revealed a decline in tumour volume which led to disappearance of the tumours in six cases and growth inhibition in two animals ( Figure 1 ). To exclude a systemic influence on tumour growth in HSVtk-expressing tumours, a follow-up was done in these tumours after sodium chloride administration showing normal growth behaviour (Figure 1 ). Figure 2 shows the normalized (SUV) PET-FDG images of animals after sodium chloride administration (Figure 2a) , and 2 days (Figure 2b ) and 4 days (Figure 2c ) after the onset of GCV therapy. After 2 days GCV treatment animals showed an increased FDG uptake as compared with the controls, whereas in four of five animals a hypometabolic area was seen in the center of the tumour after 4 days GCV therapy.
PET analysis of FDG uptake
Using a three-compartment pharmacokinetic model modified for heterogeneous tissues, the rate constants for FDG transport and phosphorylation were calculated from the dynamic PET data of control animals (n = 8) which received sodium chloride, animals after 2 days treatment with GCV (n = 7) and animals after 4 days of GCV application (n = 5). The variation coefficients (mean ± s.d.) of parameter estimation were 25 ± 18%, 30 ± 18% and 11 ± 5% for rate constants K 1 , k 2 and k 3 , respectively. We found a significant increase of K 1 after 2 days of treatment (P Ͻ 0.001), whereas after 4 days of GCV therapy K 1 was not different (P = 0.622) from the value in the control animals ( Figure 3a and Table 1 ). Also, k 2 was significantly enhanced after 2 days of therapy (P = 0.014), while no change was observed after 4 days of GCV treatment (P = 0.171; Figure 3b ). In contrast, k 3 was unchanged after 2 days therapy (P = 0.232) and enhanced after 4 days GCV administration (P = 0.006; Figure 3c ). An HPLC analysis of tumour lysates was carried out for three animals of each group, revealing 91.9 ± 3.8% (control tumours), 91.8 ± 6.3% (tumours after 2 days GCV therapy) and 97.0 ± 4.2% (tumours after 4 days GCV therapy) of FDG-6-phosphate compared with the total radioactivity (FDG and FDG-6-phosphate). The difference between the groups was not statistically significant. The metabolic rate was also enhanced after 2 days, however, with no statistical significance (P = 0.054) and no change was seen after 4 days (P = 0.222; Figure 3d ).
PET quantification using the SUV (SUV PET ) showed an enhancement of FDG uptake after 2 days (P = 0.009) and 
no change after 4 days of GCV treatment (P = 0.622; Figure 3e ). The ex vivo data (SUV WC ) revealed no statistically significant differences (P = 0.072 for 2 days and P = 0.524 for 4 days of treatment with GCV) as compared with the control group ( Figure 3f ). The SUV WC (measured by well counter 90 min post-injection (p.i.)) and the SUV PET (measured by PET 80-90 min p.i.) were correlated with r = 0.853 (significant at the 0.1% level; Figure 4 ).
Thymidine incorporation into DNA
In order to assess the effects of gene therapy with the HSVtk/GCV system on DNA synthesis, we determined the thymidine incorporation into the DNA of untreated and treated tumours ( Figure 5 ). After 2 days GCV therapy, no significant change of thymidine incorporation into the tumour DNA was observed (P = 0.189). However, we found a significant decrease of thymidine incorporation (P = 0.002) to 10.5% of the controls after 4 days of treatment with GCV. 
Discussion
In our study, we observed a growth inhibition in HSVtkexpressing Morris hepatoma, where a significant decrease in tumour volume occurred after 5 days of GCV treatment and no change in the LXSN6 control tumour ( Figure 1 ). However, immune reactions to antigens of the foreign enzyme, which may be presented after intracellular processing on the tumour cell surface, may influence the tumour growth behaviour. To exclude these systemic effects on the growth behaviour of the HSVtk-expressing tumours, we also measured the tumour volume in the HSVtk-expressing hepatomas during daily administration of sodium chloride and found no evidence for growth delay. Monitoring of gene therapy using imaging procedures for the assessment of morphological changes has been performed with magnetic resonance imaging techniques in rats bearing C6 rat glioblastomas and also in patients with glioblastoma. [11] [12] [13] In these studies, either marked tumour necrosis after interleukin-2 gene transfer or regression after induction of HSVtk expression and GCV application were observed. Maron et al 13 found an initial response to GCV treatment in 90% of the animals and a complete regression in two-thirds of the treated rats. Also, tumour recurrence could be observed. However, in these studies the therapeutic efficacy was evaluated using changes in tumour volume with examination intervals of 2 months between the end of the treatment and the first follow-up examination. 12 The measurement of metabolic changes after therapeutic intervention has proven to be superior to morphological procedures for the assessment of early therapy effects. In this respect, the FDG uptake has been demonstrated to be a useful parameter for the evaluation of glucose metabolism. [5] [6] [7] [8] [9] Since the HSVtk/GCV system induces DNA chain termination, 14 we also expect changes in thymidine incorporation into tumour cell DNA.
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C-thymidine has been applied to determine DNA synthesis in vivo. [15] [16] [17] [18] Therefore, a double tracer study was performed using 18 FDG and 3 H-thymidine. We found an increase of the FDG transport after 2 days of GCV treatment which normalized after 4 days and an increase of the phosphorylation rate after 4 days therapy (Figures 2 and 3) . Quantification by metabolic rate and a procedure which normalizes the measured activity to the injected dose and the body weight (SUV PET ) also revealed an increase of these parameters after 2 days of GCV administration. However, the difference failed to be statistically significantly different for the metabolic rate MR FDG (P = 0.054) and for the SUV WC measured ex vivo (P = 0.072).
The SUV data are influenced by patient body composition, length of the uptake period, plasma glucose level and partial volume effects (underestimation of radioactivity concentration in small structures). 19 To exclude partial volume effects on the quantification of the PET measurements, we also determined the radioactivity ex vivo in three tumour tissue samples per animal using a well counter (SUV WC ). The SUV WC and the SUV PET were highly correlated ( Figure 4) . A deviation from the line of identity was seen with an underestimation of higher uptake values by PET. This underestimation was determined by a constant multiplicative factor. Furthermore, the ROI size was not significantly different in the control group and the treated animals. Therefore, partial volume effects can be neglected as cause for systemic bias in our study. Another confounding factor may be loss of body weight during GCV therapy. We observed a weight reduction of 5-10% after 4 days and up to 30% after 8 days of GCV therapy. This shows that GCV is also a substrate for the host thymidine kinase leading to side-effects when higher doses of the drug are used. However, we performed our PET studies 2 and 4 days after the onset of GCV treatment where the small changes in weight loss are not likely to influence the SUV quantification of the PET data.
Enhancement of FDG uptake in tumour cells early after therapeutic intervention was found in vitro as well as in vivo 7, 10, [20] [21] [22] [23] [24] and has also been observed in nonmalignant tissues as an early reaction to cellular stress with a redistribution of glucose transport proteins to the plasma membrane as the underlying molecular mechanism. [25] [26] [27] Our findings of an increased inward transport 2 days after therapy fit well into previous in vitro findings of enhanced 3-O-methylglucose uptake in the same tumour cells after therapy with GCV. 10 Also, the changes in the transport constants and the metabolic rate or the SUV were congruent. The normalization of the transport rates after 4 days may be due to the therapeutic effects of DNA synthesis inhibition and the consequent death of tumour cells. This explanation is evidenced by the fact that a significant decrease of thymidine incorporation into the tumour DNA occurred only after 4 days of treatment. Furthermore, a central necrosis was seen after this period in four of five tumours (Figure 2 ).
In the in vitro study, 10 we found an increased 3-Omethylglucose uptake together with a decreased FDG phosphorylation capacity after 2 days of treatment with GCV.
10 This is at variance with our in vivo data showing an increased inward transport with a normal phosphorylation rate after 2 days and an increase of phosphorylation together with normal inward transport after 4 days. This may be caused by a different drug concentration obtained in vivo compared with the ideal in vitro situation and by the fact that in vivo tumours also contain nontumour cells such as endothelial cells, macrophages and lymphocytes, 28, 29 which lack the suicide gene transfected to the Morris hepatoma cells. These nontumour cells contribute to the signal obtained in metabolic studies as shown by MR spectroscopy. 30 Another explanation for the different behaviour of the phosphorylation rate may be the small size (n = 5) of the group after 4 days of treatment which may lead to statistical problems. However, even after elimination of a tumour showing an extremely high phosphorylation rate, the difference between this group and the control group is still significant (P = 0.016).
Finally, the changes in FDG phosphorylation may be caused by redistribution phenomena in a similar way as to the glucose transporter. The hexokinases I and II are found in a soluble form and a form which is bound to the outer membrane of the mitochondria. 31 Since the mitochondrial-bound hexokinase is much less sensitive to product inhibition by glucose-6-phosphate than the soluble form and has privileged access to the mitochondrial-produced ATP, this form confers a metabolic advantage, which is needed in tissues with high dependence on glucose for the cellular metabolism as in the brain as well as in tumours. 31, 32 This form of hexokinase favours high rates of glucose-6-phosphate synthesis. Since glucose-6-phosphate is a precursor of glycolysis as well as for the biosynthesis of nucleic acids and phospholipids, enhanced synthesis of these compounds may be essential for rapid cell division, membrane biosynthesis, and repair of cell damage.
In our study, the thymidine incorporation into tumour DNA decreased after 4 days of GCV treatment ( Figure 5 ), demonstrating the efficacy of the therapy. However, in a previous in vitro study, which used 3 H-thymidine, a decrease of thymidine uptake in the nucleic acid fraction was found together with an increase in the cytoplasmic fraction, indicating that quantification of 11 C-thymidine PET studies based on the assessment of total intracellular radioactivity may fail to detect early therapy effects on the DNA synthesis. 4, 22 The interpretation of 11 C-thymidine measurements requires information about the size of the different metabolite fractions, which may be delivered by HPLC analyses of the arterial blood plasma. 17, 18 These may be used in a modelling analysis for the determination of 11 C-thymidine incorporation into the DNA. However, other nucleoside analogues with a more favourable metabolism (less metabolites) may be better candidates for the measurement of tumour proliferation. 33 In the present study, we used a stable transfected cell line with 100% of the tumour cells expressing the HSVtk gene. Such a high transduction efficiency is not achieved in vivo. However, in our previous in vitro study with the same cell line, we found a dependence of the changes in FDG transport and phosphorylation on the amount of HSVtk-expressing cells. 10 Furthermore, in vivo transduction of tumours with retroviral vectors results in suicide gene transfer not only to tumour cells but also to the endothelial cells of the tumour vasculature. This may result in changes of tumour perfusion and substrate delivery. Therefore, the use of a stable HSVtk-expressing cell line allowed the delineation of therapy-induced changes in FDG transport and phosphorylation from treatment-induced ischemia as a consequence of impaired tumour perfusion.
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In conclusion, an uncoupling of glucose transport and phosphorylation during GCV treatment of HSVtkexpressing Morris hepatoma was found. We observed an enhanced FDG transport with normal phosphorylation after 2 days of treatment as an early event after GCV administration which is interpreted as nonspecific stress reaction to the cell damaging agent. This increase in transport normalized after 4 days whereas the phosphorylation increased. The changes in the phosphorylation rate in vivo need further investigation. Quantification using the metabolic rate or the SUV showed congruent but less sensitive results compared with the modelling approach. The measurement of thymidine incorporation into the tumour DNA can be used as an indicator of therapy efficacy.
Materials and methods
The experiments were performed in compliance with German laws relating to the conduct of animal experimentation. All data were statistically analyzed using the Mann-Whitney rank sum test (SigmaStat, version 2.0; Jandel Scientific, Erkrath, Germany).
Growth inhibition
Two cell lines, LXSN6 (a control line with the empty vector; in vitro doubling time, 17.8 ± 1.0 h) and LXSNtk8 (a GCV-sensitive line bearing the HSVtk gene; in vitro doubling time, 16.8 ± 0.7 h), derived from the Morris hepatoma cell line MH3924A were used. 4 Tumour cells (4 × 10 6 ) were transplanted s.c. into the right thigh of young male adult ACI rats. A therapy study was performed 3-4 weeks later. Animals with the LXSNtk8 tumour were treated by daily i.p. injections of 100 mg GCV (Cymeven; Syntex, Aachen, Germany)/kg body weight (bw) (n = 8) or sodium chloride (n = 6), whereas animals with the LXSN6 tumour were treated with 100 mg GCV/kg bw (n = 6). The tumour size was measured every 2 days in two orthogonal dimensions and the tumour volume was calculated assuming an ellipsoid volume.
Positron emission tomography Since no effect of GCV therapy was seen on the LXSN6 tumour and also no change in FDG uptake could be observed in a previous in vitro study, 10 we concentrated on the LXSNtk8 tumour in the PET experiments. The measurements were performed 21-28 days after inoculation when the tumours had reached a diameter of more than 20 mm. Two (n = 7) or four days (n = 5) before the PET study, the animals (weighing 260-393 g) were treated by daily i.p. administration of 100 mg GCV/kg bw. A control group (n = 8) received sodium chloride for 2 days. After premedication with 50 mg ketamine (Ketanest; Parke Davis, Berlin, Germany)/kg bw and 0.5 mg N-(3′-dimethylamino-propyl)-3-propionyl-phenothiazine-phosphate (Combelen; Bayer, Leverkusen, Germany)/kg bw, the animals were kept in an inhalation narcosis with enflurane (volume-%, 0.4), nitrous oxide (flow, 1000 ml/min), and oxygen (flow, 500 ml/min) during the PET examination.
The production of 18 FDG was done according to the method described by Oberdorfer et al. 34 The radiochemical purity was determined by high performance liquid chromatography (HPLC) with values above 98%. The PET studies were performed with a PC2048-7WB whole- F time-activity profiles were calibrated using the whole blood samples, corrected for the FDG exchange between the plasma and the red blood cells, and standardized to the injected radioactivity and the body weight of the animals.
Before each PET study, the plasma glucose level (C p ) of the animals was determined using a blood glucose sensor electrode (MediSense, Waltham, MA, USA), revealing plasma glucose levels of 105 ± 21 mg% for the control group, 130 ± 57mg% for the animals after 2 days GCV therapy, and 151 ± 54 mg% for the animals after 4 days GCV treatment. The differences between the groups were not statistically significant. Simultaneously with the 18 FDG administration, 3.7 MBq (methyl-3 H)thymidine (Amersham-Buchler, specific activity, 185 GBq/mmol; radioactivity concentration, 37 MBq/ml; radiochemical purity, 97.5%) were injected.
Before the PET emission scanning, a 30-min blank scan and a 15-min transmission scan were performed using a 68 Ge rod source. The emission sinograms were corrected for scattered radiation 35 and attenuation 36 as described elsewhere. PET images with slice thickness of 8 mm (cross plane) and 11 mm (direct planes) were generated by use of a high-resolution maximum-likelihood reconstruction algorithm 37 on a DEC 3000/400 AXP workstation (Digital Equipment Corporation, Maynard, MA, USA). To minimize partial volume effects, the inplane resolution of the images was improved by the implementation of the line-spread function of the PET scanner into the process of iterative image reconstruction which resulted in an almost constant spatial resolution of 3.9 mm over the examined field-of-view. 37 The image matrix was 256 × 256 elements with a pixel size of 1 × 1 mm.
For quantitative evaluation, regions-of-interest (ROIs) were defined in the hottest area of the tumours with region sizes exceeding 114 pixels in all cases. There was no statistically significant difference of the ROI size in the different treatment groups. The FDG uptake was expressed as standardized uptake value (SUV) according to
with C the tissue activity concentration (in Becquerels per gram), D the injected dose (in Becquerels), and m the body weight (in grams). Immediately after the PET examination, the animals were killed and the tumours were removed and weighed. Three tumour samples per animal were taken for the measurement of the 18 FDG uptake in an automated NaJ(Tl) well counter (Canberra Packard) and expressed as SUV. The three tumour uptake values were averaged to yield a well-counter standardized uptake value (SUV WC ) at 90 min after tracer administration. The same tissue samples (weighing 109 ± 6 mg) were used for DNA extraction. Furthermore, an HPLC analysis of tumour lysates was done after perchloric acid extraction for three animals of each group as described elsewhere. 10 Pharmacokinetic analysis A three-compartment pharmacokinetic model, originally developed for the brain 38 and modified for heterogeneous tissues, 39, 40 was employed for the assessment of FDG transport and phosphorylation in the tumours. The rate constants that describe the compartmental fluxes include K 1 (in millilitres per minute per gramme) for forward transport of FDG, k 2 (in reciprocal minutes) for backward transport of FDG, and k 3 (in reciprocal minutes) for phosphorylation of FDG in the tumour tissue. The model configuration included three additional fit parameters: an input function time delay parameter T d (in seconds) to correct for the time delay of 18 FDG activity arrival in the extracorporeal detector loop as well as the fit parameters ␣ (dimensionless) and ␤ (in reciprocal minutes) which define the time dependence of k 2 and k 3 according to the pharmacokinetic model configuration for FDG uptake in heterogeneous tissues. 39, 40 The model configuration was realized within the ADAPT II program environment 41 on a DEC 3000/400 AXP workstation (Digital Equipment Corporation) and included nonlinear least-squares fitting for parameter estimation.
Since the lumped constant to account for the differences between glucose and FDG for transport and phosphorylation 38 is unknown for Morris hepatoma, we restricted our analysis to the FDG metabolism. Hence, the metabolic rate of FDG utilization (MR FDG ) (in micromoles per minute per gramme) was computed as described 38 
MR FDG
with C p the plasma glucose concentration (in micromoles per millilitre) and LC the lumped constant with LC = 1.
DNA extraction
Tumour pieces were minced and digested overnight at 55°C in 700 l lysis buffer (100 mm NaCl, 10 mm Tris at pH 8, 25 mm EDTA at pH 8, 0.5% sodium dodecyl sulfate, and 0.1 mg proteinase K/ml). After addition of 3 ml phenol, the lysates were washed for 30 min and rotated at 1500 g in a Heraeus Minifuge for 10 min. The supernatant was washed with 3 ml of a phenol-chloroform-isoamylalcohol (CIA; ratio, 24:1) mixture (ratio phenol/CIA, 1:1) for 15 min. After centrifugation (10 min at 1500 g), the supernatant was washed with CIA for 15 min and rotated (10 min at 1500 g) to remove the remaining phenol. To the supernatant, 0.1 vol 3 m sodium acetate and 1 vol isopropanol were added to precipitate the DNA. After centrifugation, the pellet was washed with 70% ethanol and air dried. The pellet was resuspended in water and the DNA concentration was determined photometrically at 260 nm. Thereafter, the incorporated radioactivity was measured using Pico-Fluor-15 (Canberra Packard) in a scintillation counter (LSC TRICARB 2500TR, Canberra Packard) and normalized to the DNA content (in Becquerels per milligramme of DNA).
